Psoriasis Treatment

Psoriasis Treatment


Global Psoriasis Treatment Market to Reach US$32.4 Billion by 2030

The global market for Psoriasis Treatment estimated at US$21.0 Billion in the year 2023, is expected to reach US$32.4 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2023-2030. Interleukin Inhibitors, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$11.8 Billion by the end of the analysis period. Growth in the Corticosteroids segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.6 Billion While China is Forecast to Grow at 10.7% CAGR

The Psoriasis Treatment market in the U.S. is estimated at US$5.6 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.8 Billion by the year 2030 trailing a CAGR of 10.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Psoriasis Treatment Market - Key Trends & Drivers Summarized

Why Is the Psoriasis Treatment Market Gaining Prominence in Dermatology?

The psoriasis treatment market is gaining prominence in dermatology due to the increasing prevalence of psoriasis and the growing awareness of the condition among both patients and healthcare providers. Psoriasis is a chronic autoimmune disease characterized by the rapid growth of skin cells, leading to the formation of scaly patches, redness, and inflammation. With rising rates of obesity, metabolic syndrome, and other comorbidities that exacerbate psoriasis, the demand for effective treatment options is on the rise. As healthcare professionals become more attuned to the complexities of psoriasis and its impact on patients’ quality of life, there is a growing emphasis on developing and providing comprehensive treatment strategies that encompass both physical and psychological aspects.

One of the primary factors driving the growth of the psoriasis treatment market is the increasing availability of innovative therapies, including biologics, systemic medications, and topical treatments. Recent advancements in medical research have led to the development of targeted therapies that address specific pathways involved in the pathogenesis of psoriasis. Biologics, which are derived from living cells, have revolutionized the treatment landscape by offering effective and long-lasting solutions for moderate to severe psoriasis. These new therapies not only improve symptoms but also significantly enhance the overall quality of life for patients, driving the adoption of psoriasis treatments in clinical practice.

How Are Technological Advancements and Innovations Shaping the Psoriasis Treatment Market?

Technological advancements and innovations are significantly shaping the psoriasis treatment market by improving treatment options, enhancing patient monitoring, and personalizing care. One notable development is the evolution of biologic therapies, which target specific components of the immune system to reduce inflammation and skin cell proliferation. This class of medications has expanded treatment options for patients with moderate to severe psoriasis, providing more effective and tailored solutions. The introduction of oral biologics and biosimilars is also expected to increase access to treatment and reduce costs, further driving market growth.

Additionally, advancements in telemedicine and digital health technologies are transforming the way psoriasis is managed. Remote consultations and digital monitoring tools enable healthcare providers to assess patients’ conditions more efficiently, ensuring timely adjustments to treatment plans. Mobile applications and wearable devices that track symptoms and treatment adherence are becoming increasingly popular, empowering patients to take control of their condition. This trend towards personalized and remote care is enhancing the overall treatment experience for psoriasis patients and contributing to the growth of the market.

Moreover, ongoing research and development efforts in the field of psoriasis are leading to the discovery of new therapeutic targets and treatment modalities. Clinical trials are continuously exploring novel compounds and combination therapies that offer improved efficacy and safety profiles. The expansion of treatment options, including emerging therapies and novel drug formulations, is expected to enhance patient outcomes and satisfaction. This focus on innovation and research is a critical driver of growth in the psoriasis treatment market.

Furthermore, the increasing emphasis on holistic approaches to psoriasis management is shaping treatment strategies. Healthcare providers are recognizing the importance of addressing not only the physical symptoms but also the psychological and emotional impact of psoriasis. Integrating mental health support, lifestyle modifications, and complementary therapies into treatment plans is becoming more common. This comprehensive approach is driving the demand for multifaceted treatment solutions that can effectively address the complexities of psoriasis.

What Role Do Market Dynamics and Regulatory Trends Play in Shaping the Adoption of Psoriasis Treatments?

Market dynamics and regulatory trends play a crucial role in shaping the adoption of psoriasis treatments as industries respond to changing demands for effective therapies and compliance with regulations. The increasing prevalence of psoriasis is a key driver of the market, with millions of individuals affected worldwide. As healthcare providers become more aware of the need for effective treatment options, the adoption of advanced therapies is becoming essential. The ability to provide comprehensive treatment solutions that address the diverse needs of psoriasis patients is enhancing the market`s appeal and driving adoption.

Regulatory pressures surrounding drug approvals and safety standards are also influencing the adoption of psoriasis treatments. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established stringent guidelines for the approval and monitoring of psoriasis therapies. Compliance with these regulations is essential for manufacturers seeking to bring new products to market. The focus on rigorous testing and safety profiles enhances consumer confidence in available treatments, driving their adoption among healthcare providers and patients.

The competitive landscape within the dermatology and biopharmaceutical industries is another significant factor shaping the adoption of psoriasis treatments. Numerous manufacturers are entering the market, offering a wide range of treatment options tailored to specific patient needs. This competition is driving innovation and improvements in product quality, allowing manufacturers to meet the diverse requirements of different sectors. The focus on product differentiation, including the development of novel biologics and combination therapies, is enhancing the market presence of psoriasis treatments and contributing to their widespread adoption.

Consumer preferences for effective, reliable, and safe psoriasis treatments are also influencing adoption. As patients become more informed about their treatment options, there is a growing demand for therapies that provide fast and long-lasting results. Manufacturers are responding by developing treatments that offer improved efficacy and safety profiles, including options that minimize side effects. The ability to provide high-quality psoriasis treatments that meet the evolving needs of consumers is essential for manufacturers looking to gain a competitive edge in the market.

What Factors Are Driving the Growth of the Global Psoriasis Treatment Market?

The growth in the global psoriasis treatment market is driven by several factors, including the rising prevalence of psoriasis, advancements in therapeutic options, and ongoing research and development efforts. One of the primary growth drivers is the increasing awareness and diagnosis of psoriasis among healthcare professionals and patients. Improved understanding of the condition and its implications has led to more individuals seeking treatment, creating a larger patient base that requires effective therapeutic solutions.

The advancement of innovative therapies, particularly biologics and targeted treatments, is another key factor contributing to market growth. Biologics have transformed the treatment landscape for moderate to severe psoriasis, offering more effective and personalized solutions. The emergence of oral biologics and biosimilars is expected to further increase access to treatment and reduce costs, promoting the adoption of these therapies. The continuous development of new and improved treatment options is expected to fuel market growth as more effective therapies become available.

Ongoing research and development efforts in the field of dermatology are also supporting the growth of the psoriasis treatment market. Researchers are exploring new compounds and treatment modalities that target specific pathways involved in the pathogenesis of psoriasis. This focus on innovation is paving the way for the development of targeted therapies that can provide better outcomes for patients. The investment in R&D by biopharmaceutical companies is expected to lead to the introduction of novel treatment options, driving market expansion.

Moreover, the increasing focus on patient-centered care and holistic approaches to psoriasis management is creating new opportunities for the market. Healthcare providers are recognizing the importance of addressing the psychological and emotional impact of psoriasis, leading to integrated treatment approaches that include mental health support and lifestyle modifications. This trend towards comprehensive care is driving demand for multifaceted treatment solutions that can effectively address the complexities of psoriasis.

Additionally, the impact of the COVID-19 pandemic has heightened awareness of chronic health conditions, including psoriasis. As healthcare systems adapt to new challenges, there is a renewed focus on ensuring that patients receive the necessary care and support for their conditions. This emphasis on continuity of care is expected to drive the demand for psoriasis treatments, reinforcing the market`s growth trajectory.

As these factors converge, the global psoriasis treatment market is poised for robust growth, driven by advancements in therapeutic options, expanding patient awareness, and the increasing emphasis on improving health outcomes across various healthcare sectors.

Select Competitors (Total 44 Featured) -
  • AbbVie, Inc.
  • Amgen, Inc.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.


Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Psoriasis Treatment – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Psoriasis and Psoriatic Arthritis Propels Growth in Psoriasis Treatment Market
Increasing Adoption of Biologic Therapies in Moderate to Severe Psoriasis Expands Addressable Market
Innovations in Topical Therapies Strengthen Business Case for Market Growth
Increasing Use of Psoriasis Treatment in Dermatology and Specialty Clinics Expands Market Scope
Technological Advancements in Oral and Injectable Biologics Propel Market Growth
Case Overview: Growth in Adoption of Psoriasis Treatments in At-Home and Over-The-Counter Products Expands Market Reach
Case Overview: Growth in Use of Psoriasis Treatment in Scalp and Nail Psoriasis Expands Market Reach
Technological Advancements in Light and Laser-Based Psoriasis Therapies Propel Market Growth
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Psoriasis Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Psoriasis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Psoriasis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Psoriasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Interleukin Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Interleukin Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Interleukin Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Tumor Necrosis Factor (TNF) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Tumor Necrosis Factor (TNF) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Tumor Necrosis Factor (TNF) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Vitamin D Analogues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Vitamin D Analogues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Vitamin D Analogues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: USA Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: USA 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
CANADA
TABLE 35: Canada Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Canada 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
JAPAN
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Japan 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
CHINA
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 47: China Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: China 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 50: China Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: China Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: China 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
EUROPE
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 53: Europe Recent Past, Current & Future Analysis for Psoriasis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Psoriasis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Psoriasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Europe 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
FRANCE
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 62: France Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: France 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 65: France Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: France Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: France 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
GERMANY
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 68: Germany Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Germany 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 71: Germany Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Germany 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
ITALY
TABLE 74: Italy Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Italy 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 77: Italy Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Italy 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
UNITED KINGDOM
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 80: UK Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: UK 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 83: UK Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: UK Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: UK 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
SPAIN
TABLE 86: Spain Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Spain 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 89: Spain Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Spain Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Spain 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
RUSSIA
TABLE 92: Russia Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Russia 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 95: Russia Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Russia Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Russia 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Rest of Europe Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Rest of Europe 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Psoriasis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Psoriasis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Psoriasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Asia-Pacific 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
AUSTRALIA
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 113: Australia Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Australia 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 116: Australia Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Australia Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Australia 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
INDIA
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 119: India Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: India Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: India 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 122: India Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: India Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: India 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 125: South Korea Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: South Korea 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 128: South Korea Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: South Korea Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: South Korea 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
LATIN AMERICA
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 137: Latin America Recent Past, Current & Future Analysis for Psoriasis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Psoriasis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Psoriasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 143: Latin America Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Latin America 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 146: Argentina Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Argentina 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 149: Argentina Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Argentina Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Argentina 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
BRAZIL
TABLE 152: Brazil Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Brazil 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 155: Brazil Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Brazil Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Brazil 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
MEXICO
TABLE 158: Mexico Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Mexico 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 161: Mexico Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Mexico Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Mexico 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Rest of Latin America Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Rest of Latin America 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
MIDDLE EAST
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 170: Middle East Recent Past, Current & Future Analysis for Psoriasis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Psoriasis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Psoriasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Middle East 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
IRAN
TABLE 179: Iran Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Iran 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 182: Iran Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Iran Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Iran 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
ISRAEL
TABLE 185: Israel Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Israel 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 188: Israel Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Israel Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Israel 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Saudi Arabia Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Saudi Arabia 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 197: UAE Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: UAE 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 200: UAE Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: UAE Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: UAE 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Rest of Middle East Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Rest of Middle East 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
AFRICA
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 209: Africa Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Africa 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 212: Africa Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 213: Africa Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 214: Africa 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings